See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Natural Disasters
Donald Trump
Trade War
Social Media
Stock Markets
Trade
Artificial Intelligence
Nintendo
Climate Change
Taxes
Published • loading... • Updated

Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial

Summary by curetoday.com
Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

2 Articles

All
Left
1
Center
Right
Le MondeLe Monde
Lean Left

Innovative dual therapy would improve the prognosis of some lung cancers

The combination of a monoclonal antibody with targeted therapy would allow a one-year prolongation of survival from baseline in patients with EGFR mutation.

·Paris, France
Read Full Article
curetoday.comcuretoday.com

Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

curetoday.com broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

France

France

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal